1[1]Zondor SD, et al. bevaczumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. New Drug Developments. The Annals of Pharmacotherapy,2004,38:1258～1264
2[2]Napoleone Ferrara, Kenneth J, Hillan, et al. Discovery and development of Bevacizumab, an anti - VEGF antibody for treating cancer. Nat Rev Drug Discov ,2004 May,3 (5):391～400
3[3]Kim K, et al. The Vascular Endothelial Growth Factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors, 1992,7:53～64
4[4]Kim KJ, et al. Inhibition of Vascular Endothelial Growth Factorinduced angiogenesis suppresses tumor growth in vivo. Nature,1993,362:841～844
5[5]Warren R S, et al. Regulation by Vascular Endothelial Growth Factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest ,95,1789～1797
6[6]Melnyk. O, et al. Vascular Endothelial Growth Factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res,56,921～924
7[7]Borgstrom P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti - vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res,56
8[8]Borgstrom P, et al. Neutralizing anti - vascular endothelial growth factor antibody complete inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 1998,35,1～10
9[9]Borgstrom P, et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti - VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res, 1999, 19, 4203～4214
10[10]Ostap Melnyk, et al. Neutralizing anti - Vascular Endothelial Growth Factor antibody inhibits further growth of established prostate cancer and metastases in a pre - clinical model. The Journal of Urology, 1999 Mar , 161:960～963
3Wedam SB,Low JA.Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J].Clin Oncol,2006,24(5):769.
4Dincer M,Altundag K.Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension[J].Ann Phamacother,2006,40(12):2278-2279.
5Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
6Miles DA.Management of toxicity in patients receiving therapy withBevacizumab[J].Eur J Cancer,2008,6(6):29-39.
7Scappaticc FA,Skillings JR,Holden SN,et al.Arterial thrombo-embolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab[J].Natl Cancer Inst,2007,99(16):1232-1239.
8Eremina V,Baelde HJ,Quggin SE.Role 0f the VEGF-a signaling pathway in glomerulus:evidence for crosstalk between components of the glomerular filtration barrier[J].Nephron Physiol,2007,106(2):32-37.
9Hurwitz H,Saini S.Bevacizumab in the treatment of metastatic colo-rectal:safety profile and managerment of advense events[J].Semin Oncol,2006,33(5):S26-S34.
